Expert Disagree on Adding Chemo to Targeted Drugs in EGFR+ NSCLC Expert Disagree on Adding Chemo to Targeted Drugs in EGFR+ NSCLC
Two expert analyses arrive at opposite conclusions about adding chemotherapy to targeted drugs in patients with EGFR+ metastatic non –small cell lung cancer (mNSCLC).Medscape Medical News
Source: Medscape Pathology Headlines - Category: Pathology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Pathology